| Basics |
KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals Inc is a pharmaceuticals company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases.
|
| IPO Date: |
April 9, 2015 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$557.81M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.39 | 2.96%
|
| Avg Daily Range (30 D): |
$0.26 | 2.12%
|
| Avg Daily Range (90 D): |
$0.28 | 2.57%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.21M |
| Avg Daily Volume (30 D): |
.4M |
| Avg Daily Volume (90 D): |
.44M |
| Trade Size |
| Avg Trade Size (Sh.): |
81 |
| Avg Trade Size (Sh.) (30 D): |
54 |
| Avg Trade Size (Sh.) (90 D): |
58 |
| Institutional Trades |
| Total Inst.Trades: |
708 |
| Avg Inst. Trade: |
$1.44M |
| Avg Inst. Trade (30 D): |
$.97M |
| Avg Inst. Trade (90 D): |
$1.01M |
| Avg Inst. Trade Volume: |
.1M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.39M |
| Avg Closing Trade (30 D): |
$.94M |
| Avg Closing Trade (90 D): |
$1.03M |
| Avg Closing Volume: |
91.14K |
|
|
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$-3.77
|
$-.92
|
$-.91
|
|
Diluted EPS
|
$-3.77
|
$-.92
|
$-.91
|
|
Revenue
|
$ 50M
|
$ M
|
$ M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -175.87M
|
$ -48.51M
|
$ -42.27M
|
|
Operating Income / Loss
|
$ -181.42M
|
$ -42.94M
|
$ -45.81M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ 145.68M
|
$ 127.61M
|
$ 9.33M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Nov 22, 2016:
1:14
|
|
